About US
Contact us
-
Need proof that CV outcomes are make-or-break? See Merck's reaction to anacetrapib trial winFew thought Merck & Co.’s cholesterol-fighting candidate anacetrapib would hit its phase 3 trial goals. After all, three other drugs in the CETP inhibitor class failed dismally. But anacetrapib pu2017/6/14
-
FDA warning slams drugmaker that made teething tablets containing belladonnaAn FDA warning letter has slammed the New Jersey CMO that produced belladonna-treated teething products sold by CVS thatthe agency last year warnedmight cause hallucinations and seizures in infants.2017/6/14
-
Star-Tech & JRS Specialty Products Co., Ltd Chinese site receives EXCiPACT GMP certification as pharmaceutical excipient suppliersSTAR-TECH & JRS SPECIALTY PRODUCTS CO., LTD CHINESE SITE RECEIVESEXCiPACT GMP CERTIFICATION AS PHARMACEUTICAL EXCIPIENTSUPPLIERSBrussels, 08 June 2017EXCiPACT asbl is delighted to announce t2017/6/9
-
Synlogic completes first phase in ongoing R&D collaboration with AbbVieUS-based pharmaceutical firm Synlogic has met the first discovery milestone in its ongoing research and development (R&D) collaboration with AbbVie. In the completed first discovery phase, Synlog2017/6/9
-
Roivant forms new subsidiary to develop urology therapiesHealthcare firm Roivant Sciences has formed a new subsidiary known as ‘Urovant Sciences’ to develop new therapies for addressing urologic conditions. Urovant has licensed global rights, except in cer2017/6/8
-
Lundbeck secures rights to IBC's research for Alzheimer's treatmentDanish pharmaceutical company Lundbeck has signed an agreement to secure the rights of biotech firm ImmunoBrain Checkpoint’s (IBC) breakthrough research in Alzheimer's disease treatment. The research2017/6/8
-
Novartis and IBM Watson to optimise cancer care and patient outcomesNovartis has partnered with IBM Watson Health on an outcome-based initiative for patients with advanced breast cancer. The collaboration will involve research on a cognitive solution that uses real-w2017/6/7
-
Merck and F-star to develop five bispecific immuno-oncology antibodiesGerman science and technology firm Merck has entered a new strategic collaboration with UK-based biopharmaceutical firm F-star to develop and commercialise five bispecific immuno-oncology antibodies.2017/6/7
-
Innate Pharma acquires anti-C5aR antibody from Novo NordiskFrench biotechnology company Innate Pharma has signed an agreement to acquire a clinical-stage anti-C5a receptor (C5aR) antibody (IPH5401) from Danish pharmaceutical firm Novo Nordisk for €40m. The m2017/6/6
-
UK CMA accuses Merck of breaking competition law with discount schemeThe UK Competition and Markets Authority (CMA) has accused US pharmaceutical company Merck Sharp & Dohme(MSD) of operating an anti-competitive discount scheme for its medicine Remicade. Remicade2017/6/6